(Image source: The Carter Center)
On December 29, 2024, local time, the Carter Center issued a statement announcing the passing away of former President Jimmy Carter at his home in southeast Georgia, USA, at the age of 100. The Carter Center’s official website states that Carter served as the 39th President of the United States from 1977 to 1981. One of his most notable achievements was the formal establishment of diplomatic relations between China and the United States during his tenure.
Carter once said in a statement: “I believe that in the long run, the American people will find that getting along well with China is vital to our own prosperity, our own peace, and a good life.” The Carter Center’s official website also notes that Carter dedicated his life to the cause of peace and was awarded the Nobel Peace Prize in 2002. In addition to facilitating the establishment of diplomatic relations between China and the United States, he also played a role in the signing of the Camp David Accords between Egypt and Israel, which were significant in the Middle East peace process.
Due to his benevolent policies and his global leadership, Chinese netizens affectionately referred to him as “the benevolent ancestor of America.” Carter, who lived to be 100, is one of the longest-lived American presidents. In his 100 years of brilliant life, besides the good name left by his benevolent governance, another widely circulated story is related to Keytruda. In 2015, at the age of 90, Carter suffered from melanoma with liver and brain metastases, on the brink of death. However, after treatment with Keytruda, Carter recovered within four months, and no cancer cells were detected in his body.
Keytruda was approved for marketing in the United States in 2014. It can be said that President Carter’s story indeed made a loud “signboard” for Keytruda, which had only been on the market in the United States for one year, enhancing its reputation.
In 2023, Keytruda topped the list of the best-selling drugs of the year, becoming the new “drug king” after Humira. However, with the approval and rapid sales growth of a number of weight loss drugs, the industry also speculated that Keytruda might become the shortest-lived drug king. But according to the recent prediction analysis article on the top ten best-selling drugs globally in 2025, published in the “Nature Reviews Drug Discovery” magazine, Keytruda may still hold the throne of drug king this year. The article points out that Keytruda is still expected to be the best-selling drug in 2025, followed by the excellent performance of Ozempic in the weight loss field and its competitor Mounjaro, which matches the sales performance of these drugs in the first three quarters of this year.
【Editor’s note】The above content (~2500 words) is a quick translation of a Chinese article (posted on 2024-12-30) by DrugTimes team. To read the original article, please click here. All comments are warmly welcome. Many thanks!
发布者:DrugTimes001,转载请首先联系contact@drugtimes.cn获得授权